Semaglutide

What Is Semaglutide?

Semaglutide is a synthetic long-acting analogue of human glucagon-like peptide-1 (GLP-1), engineered with fatty-acid modification for extended plasma half-life. CertaPeptides supplies semaglutide for laboratory research in two formats: lyophilized powder (for injectable research protocols) and oral tablet form (3mg and 7mg).

CAS: 910463-68-2. Molecular formula: C₁₈₇H₂₉₁N₄₅O₅₉. Molecular weight: 4113.58 g/mol.

What Published Clinical Research Has Reported

The statements below are direct attributions to peer-reviewed clinical trial publications. They describe outcomes measured in specific trial populations under specific protocols, and are reported here for research context only. They are not claims about what CertaPeptides' research compound will do in any individual.

Cardiovascular outcomes — SUSTAIN-6 trial

Marso et al. (2016) reported, in the SUSTAIN-6 pre-specified cardiovascular outcome trial of 3,297 patients with type 2 diabetes at high cardiovascular risk, that the primary composite outcome (first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) occurred in 6.6% of the semaglutide group versus 8.9% of the placebo group over a median 2.1-year follow-up (HR 0.74; 95% CI 0.58–0.95; p<0.001 for non-inferiority). Source: New England Journal of Medicine, 2016;375(19):1834–1844. PMID 27633186.

Body weight change — STEP 1 trial (adults with overweight/obesity)

Wilding et al. (2021) reported, in the STEP 1 double-blind placebo-controlled trial of 1,961 adults with BMI ≥30 (or ≥27 with comorbidities) and without diabetes, a mean change in body weight from baseline to week 68 of −14.9% in the semaglutide 2.4 mg once-weekly group versus −2.4% in the placebo group (estimated treatment difference −12.4 percentage points; 95% CI −13.4 to −11.5; p<0.001). Source: New England Journal of Medicine, 2021;384(11):989–1002. PMID 33567185.

Body weight and glycaemic change — STEP 2 trial (adults with type 2 diabetes)

Davies et al. (2021) reported, in the STEP 2 trial of 1,210 adults with BMI ≥27 and type 2 diabetes, a mean change in body weight from baseline to week 68 of −9.6% in the semaglutide 2.4 mg group versus −3.4% in the placebo group, along with mean HbA1c change values of −1.6 percentage points versus −0.4 percentage points respectively. Source: The Lancet, 2021;397(10278):971–984. PMID 33667417.

Cardiovascular outcomes without diabetes — SELECT trial

Lincoff et al. (2023) reported, in the SELECT trial of 17,604 patients aged ≥45 years with pre-existing cardiovascular disease and BMI ≥27 but without diabetes, that a primary composite cardiovascular endpoint occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group over a mean 39.8 months of follow-up (HR 0.80; 95% CI 0.72–0.90; p<0.001). Source: New England Journal of Medicine, 2023;389(24):2221–2232. PMID 37952131.

Within the Incretin Class — How Semaglutide Differs

Semaglutide is studied alongside two other research peptides in the same metabolic class: tirzepatide (dual GIP/GLP-1R agonist) and retatrutide (triple GIP/GLP-1/GCG agonist). The three differ structurally and mechanistically in ways that shape how each compound is studied:

Semaglutide's distinguishing features are: (1) the longest peer-reviewed evidence base across diabetes, obesity and cardiovascular endpoints among the three; (2) the only research compound in the class supplied in both injectable and oral tablet form, enabling comparative bioavailability and formulation studies (see peptide bioavailability across administration routes); and (3) the reference compound in class comparisons — most newer incretin peptides are benchmarked against semaglutide. Researchers working across the class frequently reference the GLP-1 class comparison overview and the semaglutide mechanism-of-action research summary.

Research Areas Where Semaglutide Is Studied

• GLP-1 receptor pharmacology and in vitro receptor-binding assays
• Preclinical metabolic models (rodent glucose homeostasis, energy expenditure)
• Comparative studies vs dual/triple agonists (tirzepatide, retatrutide) in research settings
• Peptide stability and formulation research (oral vs injectable routes)

Specifications

Storage

Lyophilized powder: −20°C for long-term storage. 2–8°C for short-term use.

Reconstituted: 2–8°C, use within 4 weeks. Do not freeze after reconstitution.

Oral tablets (3mg/7mg): Room temperature, dry, sealed. Keep away from light.

Quality Assurance

• HPLC analysis confirms 99.3% avg purity
• Mass spectrometry verifies molecular identity
• Certificate of Analysis (COA) included with every order
• EU-based quality control under CERTALAB S.R.L.

Important Notice — Research Use Only

Semaglutide is supplied by CertaPeptides strictly as a laboratory research compound. The clinical-trial figures cited above are taken from peer-reviewed human clinical trials (SUSTAIN-6, STEP 1, STEP 2, SELECT) published in NEJM and The Lancet, and are reported here for research context only. They are not medical claims and do not describe what CertaPeptides' research material will do in any individual. This product is not a drug, not a dietary supplement, not a cosmetic, and not approved by the FDA, EMA, or any other regulatory authority for over-the-counter sale for human or veterinary use. It is not intended to diagnose, treat, cure, prevent, or mitigate any disease or condition. For laboratory research purposes only. Not for human consumption.